The approval gives patients with advanced pancreatic cancer a new treatment option, and one related vaccine approach reported immune responses in most patients.

Family-funded research helped bring a gene therapy for the rare Sanfilippo syndrome to regulatory approval, highlighting the role of patient advocacy in drug de

The first mRNA vaccine against cancer and related personalized approaches are being widely examined as a potential shift in oncology treatment.

The expanded clearance broadens access to the CRISPR-based therapy for sickle cell disease, though reimbursement questions remain.

Investor enthusiasm for gene editing rose after conference data and new regulatory draft guidance.

The proposed withdrawal would remove a marketed therapy from the US, a rare regulatory reversal.

The approval marks a new modality for treating the rare condition caused by HPV.

Policymakers and lobbyists outline how the midterm elections could change American health care.

The advisory vote could expand compounding access to peptides, a closely watched regulatory question.

Chronic care drugs led the sustained growth in India's pharmaceutical market.

Merck's personalized oncology approach and a strong stock run are drawing investor attention.

The milestone moves a mitochondrial disease candidate into mid-stage clinical testing.

The Indian biotech startup aims to manufacture more than 100 personalized cancer vaccines in 12 months.

Multiple large drugmakers are racing to develop new prostate cancer therapies.

Analysis of cancer drug pricing shows large mark-ups have returned, echoing earlier patterns.

New data support a triplet regimen as front-line treatment for a specific melanoma mutation.

A blood-based mRNA model may help identify patients likely to develop resistance to hormone therapy.

The founders behind the company's mRNA platform were recognized with a science prize, underscoring their role in vaccine development.